



Curriculum Vitae

Personal information Hedvig Marie Egeland Nordeng

Work experience

- Employer:** University of Oslo
Position: Professor and Head of the PharmacoEpidemiology and Drug Safety (PharmaSafe) Research Group
Start date: January 2011 — Present
Activities: [PharmaSafe Research Group](#)
Affiliation: Department of Pharmacy, Faculty of Mathematics and Natural Sciences
Country: Norway
- Institution:** University of Southern Denmark
Position: Adjunct Professor in Clinical Pharmacology
Start date: 2024 — Present
Faculty: Faculty of Health Sciences
Country: Denmark
- Employer:** Norwegian Institute of Public Health (NIPH)
Position: Senior Researcher (20%)
Start date: January 2006 — Present
Department: Department of Child Health and Development
Activities: Research
Country: Norway
- Employer:** University of Oslo
Position: Postdoctoral Fellow, Drug Safety in Pregnancy
Start date: January 2005
End date: December 2007
Activities: Research on drug safety in pregnancy
Department: Department of Pharmacotherapy, Faculty of Medicine
Country: Norway
- Employer:** Regional Drug Information Centre, Rikshospitalet Hospital
Position: Drug Information Specialist (part-time)
Start date: January 2005
End date: December 2005
Activities: Drug information and adverse drug reaction (ADR) reporting
Country: Norway

Education and training

- Subject:** University of Oslo
 - Start date: 011999
 - End date: 122004
 - Qualification: PhD in Pharmacoepidemiology
 - Organisation: Focus: perinatal pharmacoepidemiology and pharmacotherapeutics in pregnancy
 - Country: Norway
- Subject:** University of Oslo
 - Start date: 011992
 - End date: 121997
 - Qualification: M.Sc. and B.Sc. in Pharmacy
 - Organisation: Department of Pharmacy
 - Country: Norway
- Subject:** Lycée Edouard Herriot, Lyon
 - Start date: 011987
 - End date: 121992
 - Qualification: Baccalauréat Française
 - Organisation: Lycée Edouard Herriot
 - Country: France

Additional information

Publications

Summary I have in total over 270 published publications. My overall H index is 50 according to Scopus. The total number of citations is over 7000.

Medication Safety and Use in Pregnancy

- Boissiere-O'Neill T, van Gelder MMHJ, Engjom HM, Nordeng HME. Exposure to Systemic Antimicrobials During Pregnancy and Risk of Miscarriage: A Population-Based Registry Study. BJOG. 2025 Mar 28. doi: 10.1111/1471-0528.18155.
- Christensen JJ, Bogsrud MP, Holven KB, Retterstøl K, Veierød MB, Nordeng H. Use of statins and other lipid-modifying agents across pregnancy: A nationwide drug utilization study in Norway in 2005-2018. Atherosclerosis. 2023 Mar;368:25-34.
- Nezvalová-Henriksen K, Wood M, Spigset O, Nordeng H. Association of Prenatal Ibuprofen Exposure with Birth Weight and Gestational Age: A Population-Based Sibling Study. PLoS One. 2016 Dec

9;11(12):e0166971.

- Lupattelli A, Wood M, Lapane K, Spigset O, Nordeng H. Risk of preeclampsia after gestational exposure to selective serotonin reuptake inhibitors and other antidepressants: A study from The Norwegian Mother and Child Cohort Study. *Pharmacoepidemiol Drug Saf.* 2017 Oct;26(10):1266-1276.

Long term neurodevelopmental outcomes:

- Sundbakk LM, Wood M, Gran JM, Nordeng H. Prenatal exposure to benzodiazepine and z-hypnotics and fifth-grade scholastic skills-emulating target trials using data from the Norwegian Mother, Father and Child Cohort Study. *Am J Epidemiol.* 2025 Jan 8;194(1):73-84.
- Sundbakk LM, Gran JM, Wood ME, Handal M, Skurtveit S, Nordeng H. Association of Prenatal Exposure to Benzodiazepines and Z-Hypnotics With Risk of Attention- Deficit/Hyperactivity Disorder in Childhood. *JAMA Netw Open.* 2022;5(12):e2246889.
- Ystrom E, Gustavson K, Brandlistuen RE, Knudsen GP, Magnus P, Susser E, Davey Smith G, Stoltenberg C, Surén P, Håberg SE, Hornig M, Lipkin WI, Nordeng H, Reichborn-Kjennerud T. Prenatal Exposure to Acetaminophen and Risk of ADHD. *Pediatrics.* 2017;140(5):e20163840.
- Frank AS, Lupattelli A, Brandlistuen RE, Nordeng H. Maternal Thyroid Hormone Replacement Therapy Exposure and Language and Communication Skills of Offspring at 8 Years of Age. *JAMA Netw Open.* 2019;2:e1912424.
- Lupattelli A, Wood M, Ystrom E, Skurtveit S, Handal M, Nordeng H. Effect of Time-Dependent Selective Serotonin Reuptake Inhibitor Antidepressants During Pregnancy on Behavioral, Emotional, and Social Development in Preschool-Aged Children. *J Am Acad Child Adolesc Psychiatry.* 2018 Mar;57(3):200-208.

Other long term outcomes:

- Hemmingsen CH, Kjaer SK, Hjorth S, Nörby U, Broe A, Pottegård A, Bénévnt J, Schmiegelow K, Skovlund CW, Leinonen MK, Nordeng H, Mørch LS, Hargreave M. Maternal use of hormonal contraception and risk of childhood leukemia: A Scandinavian population-based cohort study. *Eur J Cancer.* 2025 Jan 17;215:115168. doi: 10.1016/j.ejca.2024.115168.

Registry Methodology

- Nordeng HME, Lupattelli A, Engjom HM, van Gelder MMHJ. Detecting and Dating Early Non-live Pregnancy Outcomes: Generation of a Novel Pregnancy Algorithm From Norwegian Linked Health Registries. *Pharmacoepidemiol Drug Saf.* 2024;33(9).
- Trinh N, Houghtaling J, Martinez FL, et al. Harmonizing Norwegian registries onto OMOP common data model: Mapping challenges and opportunities for pregnancy and COVID-19 research. *Int J Med Inform.* 2024;191:105602.

COVID-19

- Trinh NT, Jödicke AM, Català M, Mercadé-Besora N, Hayati S, Lupattelli A, Prieto-Alhambra D, Nordeng H. Effectiveness of COVID-19 vaccines to prevent long COVID: data from Norway. *Lancet Respir Med.* 2024 May;12(5):e33-e34.
- Orangzeb S, Desalegn A, Trinh NTH, Zhao J, Nordeng H, Lupattelli A. COVID-19 vaccine uptake among children and adolescents in Norway: A comprehensive registry-based cohort study of over 800,000 individuals. *Vaccine.* 2024 May 31;42(15):3420-3428.
- Ukah UV, Platt RW, Nordeng HME. Impact of COVID-19 Pandemic on Dispensing of Cardiovascular Drugs in Norway: An Interrupted Time Series Study. *Am J Prev Med.* 2024 Apr;66(4):672-680.
- Elyass J, Desalegn A, Trinh NTH, Orangzeb S, Zidan M, Nordeng H, Lupattelli A. Individual and familial factors associated with mRNA COVID-19 vaccine uptake in pregnancy: A large-scale registry-based linkage study. *Vaccine.* 2024 Aug 30;42(21):126171.
- Pedersen E, Tripodi E, Aakjær M, Li H, Cantarutti A, Nyberg F, Andersen M, Lupattelli A, Nordeng H. Drug utilisation in children and adolescents before and after the start of the COVID-19 pandemic: Interrupted time-series analyses in three European countries. *Paediatr Perinat Epidemiol.* 2024 Aug;38(6):450-460.
- Moreno-Martos D, Zhao J, Li H, Nyberg F, Bjørndal LD, Hajiebrahimi M, Wettermark B, Aakjær M, Andersen M, Sessa M, Lupattelli A, Nordeng H, Morales DR. Impact of the early COVID-19 pandemic on adult mental health-related dispensed medications, hospitalizations and specialist outpatient visits in Norway and Sweden: Interrupted time series analysis. *Br J Clin Pharmacol.* 2024 Jul;90(7):1627-1636.
- Tauqeer F, Ceulemans M, Gerbier E, Passier A, Oliver A, Foulon V, Panchaud A, Lupattelli A, Nordeng H. Mental health of pregnant and postpartum women during the third wave of the COVID-19 pandemic: a European cross-sectional study. *BMJ Open.* 2023 Jan 11;13(1):e063391.
- Hurley E, Geisler BP, Lupattelli A, Poblador-Plou B, Lassalle R, Jové J, Bernard MA, Sakr D, Sanfeliu-Gimeno G, Sánchez-Saez F, Rodríguez-Bernal CL, Sabaté M, Ballarín E, Aguilera C, Jordan S, Thayer D, Farr I, Ahmed S, Bartolini C, Limoncella G, Paoletti O, Gini R, Maglanoc LA, Dudukina E, Ehrenstein V, Alsina E, Vaz TA, Riera-Arnau J, Sturkenboom MCJM, Nordeng HME. COVID-19 and pregnancy: A European study on pre- and post-infection medication use. *Eur J Clin Pharmacol.* 2024 May;80(5):707-716.

Breast feeding and medication safety

- Nordeng H, Wegler C, Lindqvist A, Melander E, Magnusson M, Gandia P, Panchaud A, Baranczewski P, Spigset O. Transfer of cetirizine/levocetirizine into human breast milk and estimation of drug exposure to infants through breastfeeding: A human lactation study from the ConcePTION project. *Basic Clin Pharmacol Toxicol.* 2024 Jan;134(1):153-164.
- Melander E, Nielsen EI, Lindqvist A, Hovd M, Gandia P, Panchaud A, Guidi M, Annaert P, Baranczewski P, Spigset O, Nordeng H. Population pharmacokinetic modelling of cetirizine concentrations in human breast milk-A contribution from the ConcePTION project. *Basic Clin Pharmacol Toxicol.* 2025 Jan;136(1):e14100.
- Amundsen S, Nordeng H, Fuskevåg OM, Nordmo E, Sager G, Spigset O. Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding. *Basic Clin Pharmacol Toxicol.* 2021 Jun;128(6):795-804.
- Nordeng H, Gjerdalen G, Brede WR, Michelsen LS, Spigset O. Transfer of aripiprazole to breast milk: a case report. *J Clin Psychopharmacol.* 2014 Apr;34(2):272-5.

Paternal Medication Safety

- Meng LC, van Gelder MMHJ, Chuang HM, et al., Nordeng HME. Paternal metformin use and risk of congenital malformations in offspring in Norway and Taiwan: population based, cross-national cohort study. *BMJ.* 2024;387:e080127.
- Meng LC, van Gelder MMHJ, Chuang HM, Lai HY, Chen LK, Hsiao FY, Nordeng HME. Valproate Use by Fathers and Risk of Neurodevelopmental Disorders in Children. *NEJM Evid.* 2026

Mar;5(3):EVIDoa2500254. doi:

10.1056/EVIDoa2500254. Epub 2026 Feb 24. PMID: 41733407.

Methodological Contributions

- Damkier P, Huybrechts KF, Nordeng H. Big Data in the Assessment of Medication Safety in Pregnancy: Opportunities and Challenges. *Paediatr Drugs*. 2025 Nov;27(6):673-677.
- Lupattelli A, Trinh NTH, Nordeng H. Association of maternal personality traits with medication use during pregnancy to appraise unmeasured confounding in long-term pharmacoepidemiological safety studies. *Front Pharmacol*. 2023 May 15;14:1160168.
- van Gelder MMHJ, Lupattelli A, Nordeng HME. Risk of spontaneous abortion after periconceptional medication use: Time to tackle the methodological challenges. *Paediatr Perinat Epidemiol*. 2023 Mar;37(3):188-190.
- Lupattelli A, Wood ME, Nordeng H. Analyzing Missing Data in Perinatal Pharmacoepidemiology Research: Methodological Considerations to Limit the Risk of Bias. *Clin Ther*. 2019 Dec;41(12):2477-2487.
- Cohen JM, Wood ME, Hernández-Díaz S, Ystrom E, Nordeng H. Paternal antidepressant use as a negative control for maternal use: assessing familial confounding on gestational length and anxiety traits in offspring. *Int J Epidemiol*. 2019;48:1665-1672.
- Wood ME, Lapane KL, van Gelder MMHJ, Rai D, Nordeng HME. Making fair comparisons in pregnancy medication safety studies: An overview of advanced methods for confounding control. *Pharmacoepidemiol Drug Saf*. 2018;27(2):140-147.
- Wood ME, Lupattelli A, Palmsten K, Bandoli G, Hurault-Delarue C, Damase-Michel C, Chambers CD, Nordeng HME, van Gelder MMHJ. Longitudinal Methods for Modeling Exposures in Pharmacoepidemiologic Studies in Pregnancy. *Epidemiol Rev*. 2022 Jan 14;43(1):130-146.

Genetics, Epigenetics and Child Neurodevelopment

- Olstad EW, Nordeng HME, Bjørk MH, Selmer K, Gervin K. Paternal valproate use and impact of shared genetic susceptibility on child neurodevelopment. *Sci Rep*. 2025 Nov 7;15(1):39033. doi: 10.1038/s41598-025-23377-1.
- Olstad EW, Nordeng HME, Sandve GK, Lyle R, Gervin K. Effects of prenatal exposure to (es)citalopram and maternal depression during pregnancy on DNA methylation and child neurodevelopment. *Transl Psychiatry*. 2023 May 5;13(1):149.
- Gervin K, Nordeng H, Ystrom E, Reichborn-Kjennerud T, Lyle R. Long-term prenatal exposure to paracetamol is associated with DNA methylation differences in children diagnosed with ADHD. *Clin Epigenetics*. 2017;9:77.
- Gervin K, et al. Cell type specific DNA methylation in cord blood: A 450K-reference data set and cell count-based validation of estimated cell type composition. *Epigenetics*. 2016;11:690-698.

Projects

MAJOR GRANTS:

2026 - 20230 UIORealWorld Evidence: Capitalizing on Norwegian Health Data for Rapid Generation of Real-World Evidence on Effectiveness and Safety of Pharmaceuticals: – Project leader – UiO Life Science Convergence Environment (16 mill NOK).

2022 - 2026 UIORealArt: Real world – artificial worlds: Improving causal inference in perinatal pharmaco_epidemiology using machine learning approaches on real-world and artificial data – Project leader _ UiO Life Science Convergence Environment (16 mill NOK).

2021- 2025 [International Alliance for Pharmacogenetic Epidemiology Excellence \(iAPOGEE\)](#) - Project leader – RCN, INTPART International Partnerships for Excellent Education, Research and Innovation (10 mill NOK)

2020 - 2023 Nordic COHERENCE (Nordic COLlaborative HEalth REgister Network for Covid-19 Epidemiology) – Work package lead on vulnerable patient groups – Nordforsk – (2.5 M NOK)

2020 _ 2022 EU_COVID_19 – Project leader – NFR (4.97 M NOK)

2015 _ 2020 DrugsInPregnancy (STG GA No. 639377) – Project leader – ERC (1.5 M EUR)

2019 _ 2024 ConcePTION – Partner, task lead 1.5 – IMI H2020 (13 M EUR Total, 52 partners).

2019 _ 2023 PharmaTox 2.0– Project leader – UiO MN, Strategic Research Initiative (0.9 M EUR)

2015 _ 2020 PharmaTox 1.0– Project leader – UiO MN, Strategic Research Initiative (1.8 M EUR)

2015 _ 2020 The PharmaTox Honours Program in Quantitative Life Sciences – Project leader – RCN, INTPART International partnerships (440 k EUR)

2012 – 2016 Grants for 1 post doc and 2 PhD positions from non_profit organizations "Extrastiftelsen" & "Sanitetskvinnene"

Memberships

MEMBERSHIPS OF SCIENTIFIC SOCIETIES:

_ European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EnCePP)

_ International Society of Pharmacoepidemiology (ISPE), FISPE

_ European Drug Utilization Research Group (EuroDRUG)

_ Organization of Teratology Information Specialists (OTIS)

_ European Network of Teratology Information Specialists (ENTIS)

_ Nordic Pharmacoepidemiology Network (NorPEN)

_ COST network; Research Network in Peripartum Depression Disorder (*national contact person for Norway*)

Other Relevant Information

Hedvig Nordeng. is a professor and head of the Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo (UiO), Norway. Professor Nordeng's has more than 20 years of research experience in pharmacoepidemiology based on health registry data in Norway, and in specific populations such as pregnant individuals and children. She has a long track record of interdisciplinary research and of international research projects, using large population-based cohorts and linked health care registries, especially in the Nordic countries. Over the past years, she has put great efforts into creating a data analytical pipeline at the University of Oslo for rapid analysis of urgent perinatal pharmacovigilance signals. Her research group: [PharmacoEpidemiology](#)

Her research group is a data partner in DARWIN EU, VAC4EU and European Health Data & Evidence Network (EHDEN).

Honors

- 2024: The NAR Brain Power Award, awarded by Forskerforbundet / The Norwegian Association of Researchers for significant contributions to society through knowledge-based work.
- 2023: Women's Research Award from the Norwegian Women's Public Health Association, Norway's largest women's organization, for research to improve women's health.
- 2020: Appointed Fellow of ISPE (International Society of Pharmacoepidemiology).
- 2017: Titan-award for outstanding dissemination of research within Natural Sciences. First award winner, Faculty of Mathematics and Natural Sciences, University of Oslo.
- 2016: Pharmacist of The Year in Norway, awarded by The Norwegian Association of Pharmacists